10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Pfizer has announced positive top-line results from a Phase III study of etrasimod in moderately to severely active ulcerative colitis (UC). 24 March 2022
In the latest in a series of life sciences SPAC mergers, Ligand Pharmaceuticals is to use the approach to hive off its antibody business. 24 March 2022
Finnish drugmaker Orion Corp’s shares edged up 2% this morning, after it said that its R&D function is planning to refocus efforts on the development of new proprietary products from several therapy areas to two, cancer diseases and pain 24 March 2022
Californian gene specialist Mammoth Biosciences, a three-year old biotech focused on developing CRISPR products, has made a new senior executive appointment. 24 March 2022
As well as offering a batch of proposals to relieve households facing a crippling cost of living crisis, UK Chancellor Rishi Sunak’s Spring Statement yesterday included a number of relevant announcements for the pharmaceutical industry. 24 March 2022
Arenaviral immunotherapies company Hookipa Pharma has announced that Klaus Orlinger has been promoted to the role of chief scientific officer (CSO). 23 March 2022
LifeMine Therapeutics, a US start-up searching the fungal biosphere for genetically-encoded small molecules (GEMs), has announced the completion of a $175 million Series C financing. 23 March 2022
US pharma giant Merck & Co today announced today that Dr Roy Baynes, head of global clinical development (GCD) and chief medical officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. 23 March 2022
A study of University of Hong Kong revealed that three shots of CoronaVac, developed by China-based Sinovac Biotech, offered around 98% protection against death or severe illness in those over 60 years old, underscoring the importance of boosters for those who have received that Covid-19 shot. 23 March 2022
Dutch autoimmune diseases specialist Argenx has announced positive top-line data from the Phase III ADAPT-SC study evaluating subcutaneous (SC) efgartigimod (1,000mg efgartigimod-PH20) to treat generalized myasthenia gravis (gMG). 23 March 2022
Florida, USA-based oncology focused bio-pharmaceutical firm Xcovery says its China-based affiliate Betta Pharma (SHE: 300558), which is its majority shareholder, has received approval from the National Medical Products Administration (NMPA) for ensartinib in China for the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC). 23 March 2022
A business of Fujifilm Holdings has announced it will buy USA-based recombinant protein company Shenandoah Biotechnology for an undisclosed amount. 23 March 2022
Shares of Danish biopharma firm Orphazyme were down 4.8% at 5.90 kroner by late morning today, after it announced a setback with the regulatory filing for its lead product candidate in Europe. 23 March 2022
The pharmaceutical industry is faced by a multi-dimensional challenge of revenues under pressure, increasing regulatory requirements which differ across localities, dispersed data sources, innovation in technology and staffing pressures. 23 March 2022
Nucleai, an Israeli based AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data, has closed a Series B financing for $33 million. 23 March 2022
Transdermal cannabinoid specialist Zynerba Pharmaceuticals’ pipeline drug Zygel is expected to achieve $18.1 million in sales by 2030, according to GlobalData, due to its potential to help fragile X syndrome (FXS) patients with irritability or aggression symptoms. 23 March 2022
China’s Fosun Pharma’s biotech arm Henlius is preparing to get its PD1 antibody serplulimab into hospitals nationwide once it is approved in China, and supply its four approved biosimilars with enhanced manufacturing capacity, said Henlius chief executive Zhang Wenjie at a press meeting held in Shanghai on March 17. 22 March 2022
The federal government of Australia will invest A$28.1 million ($20.9 million) into a new agency for the Health Portfolio, Genomics Australia, it has been announced. 22 March 2022
The UK’s medicine costs watchdog the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending US biotech company BioMarin Pharmaceutical Vimizim (elosulfase alfa) for routine use in the National Health Service (NHS) for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome). 22 March 2022
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024